Code intelligence

FDA-BLA761149 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761149.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ENSPRYNG (SATRALIZUMAB) — Type 1 - New Molecular Entity

Policy FDA-BLA761149 · Neurology

High

Enspryng (Satralizumab) is an injectable drug approved for Part B billing, likely leading to a new J-code assignment. With its status as an orphan drug, it may qualify for pass-through payment under M

View alert